Novavax Says Its COVID-19 Vaccine Is on Track for FDA Approval After Delay

The company is seeking licensure for its COVID-19 shot.

A dose of Novavax's COVID-19 vaccine is prepared, in this file image. Joroen Jumelet/ANP/AFP via Getty Images

A company that makes one of the three COVID-19 vaccines available in the United States said on April 23 that its shot is on track for regulatory approval, after regulators declined to grant approval before a deadline.

“We believe that our Biologics License Application (BLA) is approvable based on conversations with the U.S. Food and Drug Administration (FDA),” Novavax said in a statement.